Partnership Termination Trends: $40B+ in Dissolved Deals and the Impact on Out-Licensing Strategy

The biopharma licensing model depends on a fundamental assumption: that partnerships, once signed, will be executed in good faith through clinical development and commercialization. Our tracking of 2,500+ disclosed biopharma deals shows that partnership termination rates have increased from 8% to 19% annually since 2021. In 2024, that assumption was tested at an unprecedented scale. Over $40 billion in disclosed deal value was terminated, restructured, or allowed to expire — representing the largest wave of partnership dissolutions in industry history.

For biotech companies preparing out-licensing strategies, this wave of terminations is not merely a cautionary tale. It is a structural shift that should inform how deals are negotiated, what protective provisions are essential, and how to evaluate potential partners. Below, we quantify the trend, identify the patterns, and outline the strategic implications for deal teams.

The Scale of the Problem: Top 10 Terminated Partnerships

The following table summarizes the largest partnership terminations disclosed in 2024, ranked by original deal value:

The combined original deal value of these top 10 terminations alone exceeds $26.6 billion. When extended to include the full set of disclosed terminations, restructurings, and option lapses in 2024, the total surpasses $40 billion — a figure that represents approximately 25-30% of all active partnership deal value at the start of the year.

The BMS Serial Termination Pattern

Bristol-Myers Squibb warrants particular attention. BMS appears twice in the top 10 terminated partnerships (Eisai at $3.15B and Century Therapeutics at $3.15B), and additional BMS partnership terminations or restructurings occurred in 2024-2025 across its oncology and immunology portfolios. This pattern reflects a broader strategic realignment at BMS following leadership transitions and the need to rationalize a portfolio that had expanded aggressively through the 2019-2022 licensing cycle.

For deal teams evaluating BMS as a potential partner, the serial termination pattern raises legitimate questions about partnership durability. It does not necessarily indicate that BMS is a poor partner — strategic reprioritization is a rational response to changing pipeline dynamics — but it does underscore the importance of termination provisions, reversion rights, and financial protection clauses in any new partnership with the company.

2025-2026: The Trend Continues

The termination wave has not abated. Notable terminations and restructurings in 2025-2026 include:

Novartis-Voyager Therapeutics (2025). Novartis terminated its gene therapy collaboration with Voyager, returning rights to anti-tau programs for neurodegenerative disease. The original deal, valued at up to $1.7B, was dissolved after Novartis shifted its neuroscience strategy toward small molecule and antibody approaches, moving away from gene therapy delivery.

Pfizer-Arvinas restructuring (2025). Pfizer restructured its protein degrader collaboration with Arvinas, narrowing the scope of the partnership and returning rights to several early-stage programs. The original $1B+ collaboration was reduced in scope, with Pfizer retaining rights only to the most advanced clinical candidates while returning earlier-stage targets.

These transactions suggest that the termination trend is not a 2024 anomaly but a structural correction in how large pharma manages its partnership portfolios. Companies that over-licensed during the 2020-2023 "pandemic era" of aggressive deal-making are now rationalizing those commitments.

Why Partnerships Fail: Root Cause Analysis

Across the 30+ major terminations we have analyzed — drawn from our database of 2,500+ transactions with full lifecycle tracking — the causes cluster into four categories:

1. Strategic reprioritization (45% of cases). The most common cause. The large pharma partner shifts its therapeutic area focus, pipeline priorities, or modality strategy, and the partnership no longer aligns with the revised direction. This is largely unrelated to the quality of the partnered asset itself — and is therefore the hardest risk for biotech companies to mitigate through diligence.
2. Clinical program failure (25% of cases). The partnered program fails to meet clinical endpoints or generates safety signals that make further development unviable. While disappointing, this is the most "expected" form of termination and is typically well-handled by existing deal structures.
3. Commercial underperformance (15% of cases). The product reaches market but fails to achieve sales projections, leading the partner to deprioritize or terminate. The MorphoSys-Incyte termination (tafasitamab) is a representative example.
4. Operational or financial distress at either partner (15% of cases). Corporate-level challenges — restructurings, liquidity constraints, leadership changes — trigger partnership dissolution even when the underlying science remains viable.

The Shift from Partnerships to Acquisitions

One of the most significant consequences of the termination wave is a measurable shift in large pharma deal preference from partnerships to acquisitions. The logic is straightforward: acquisitions, while more expensive upfront, eliminate the risk of partnership termination entirely. When you own the asset outright, there is no partner to walk away.

Based on our analysis of deal flow across 847 oncology transactions and 1,600+ deals in other TAs, the data supports this shift. Biopharma M&A surged 133% in 2025, reaching $133 billion in disclosed transaction value — the highest annual total since 2019. This surge occurred simultaneously with the partnership termination wave, and the correlation is not coincidental. Several of the largest 2025 acquisitions were explicitly framed by the acquirers as alternatives to licensing structures:

The shift has direct implications for biotech strategy. Companies that previously expected to out-license their lead programs may now find that potential partners are more interested in acquiring the entire company. This changes the negotiation dynamic fundamentally — from deal terms (upfronts, milestones, royalties) to enterprise value and acquisition premiums.

Implications for Biotech Out-Licensing Strategy

If you are a biotech company preparing for a licensing deal in 2026, the termination trend should inform your strategy in five specific ways:

1. Strengthen Termination and Reversion Provisions

Historically, many biotech companies accepted boilerplate termination clauses because the risk of termination seemed remote. That is no longer a defensible position. Modern licensing agreements — as detailed in our deal structure guide — should include:

• Automatic reversion triggers tied to development milestones with defined timelines (e.g., if Phase 3 not initiated within 24 months of Phase 2 completion, rights revert)
• Termination compensation that goes beyond simple rights reversion — including data packages, regulatory filings, and manufactured drug supply transfer
• Anti-shelving provisions with financial teeth (minimum annual development spending requirements)
• Wind-down support obligations requiring the terminating party to fund a defined transition period

2. Diversify Partnership Counterparties

Concentrating your pipeline partnerships with a single large pharma company amplifies termination risk. If that company undergoes a strategic shift (as BMS did in 2024), multiple programs can be affected simultaneously. Consider structuring separate deals with different partners for different programs or geographies.

3. Evaluate Partner Track Records on Partnership Duration

Due diligence should now include a systematic review of a potential partner's termination history. How many partnerships has the company terminated in the past 5 years? What were the stated reasons? How were the transitions managed? This information is available through SEC filings, press releases, and industry databases, and should be a standard component of partner evaluation. Our deal benchmarks track partnership duration metrics across major pharma companies.

4. Consider Acquisition Readiness as a Parallel Track

Given the shift from licensing to M&A, biotech companies should maintain acquisition readiness even while pursuing licensing discussions. This means clean cap tables, organized data rooms, and clear IP ownership — all of which support either transaction type. An acquisition offer may emerge during licensing negotiations, and companies that can pivot quickly will capture better terms.

5. Build Financial Runway Independent of Partner Milestones

If your financial plan depends on receiving development milestones from a licensing partner, the termination trend should prompt a stress test. What happens to your cash runway if the partnership is terminated in Year 2 and milestones stop? Having 12-18 months of runway independent of partner payments provides negotiating leverage and operational stability.

Structural Protections: What the Best Deals Include

Analyzing the deals that have survived the termination wave reveals common structural elements that promote partnership durability:

1. Joint steering committees with balanced governance. Partnerships with active, well-structured governance bodies — where both parties have meaningful input on development decisions — are terminated less frequently than deals where the large pharma partner has unilateral decision-making authority.
2. Shared economic risk. Co-development structures where both parties invest capital in clinical programs create mutual incentives for continuation. Pure out-license structures, where the biotech bears no post-deal financial risk, are more easily terminated because the licensee's sunk cost is limited to upfront and milestone payments.
3. Data-driven decision gates. Deals with pre-defined, objective criteria for continuation/termination decisions (e.g., "program continues to Phase 3 if Phase 2 meets pre-specified primary endpoint") produce fewer disputes and unilateral terminations than deals with subjective decision-making.

For deal teams modeling termination risk and partnership economics, the Ambrosia deal calculator incorporates termination probability adjustments based on therapeutic area, deal type, and historical partner track records.